Who is Captain John Illson? IndiGo ropes in US-based aviation expert to find root cause of massive disruption ...

The blockbuster drug by Novo Nordisk will be marketed for adults with type-2 diabetes, unlike in the US and Europe where it is also sold as Wegovy for weight loss. Ozempic is a once-weekly injectable ...

Retatrutide, Eli Lilly’s triple-hormone obesity drug, delivers up to 28.7% weight loss and major knee pain relief in ...

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Recent clinical trials of Novo Nordisk’s blockbuster GLP-1 drug semaglutide for Alzheimer’s disease may have failed to show ...

YOU may be keen to shed pounds from your waistline with fat jabs, but forking out the monthly bill is less appealing – ...

But even as Ozempic enters India, there is a growing sense globally that Novo may have already lost the obesity drug war to Mounjaro, Eli Lilly’s blockbuster that has become India’s top-selling drug ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.

The class of GLP-1 agonist medications act by lowering the appetite with applications way beyond diabetes. These medicines ...

Novo Nordisk’s blockbuster diabetes drug, Ozempic, was officially launched in India on December 12. Unlike in the US and ...

Danish pharmaceutical company Novo Nordisk today launched its blockbuster type 2 diabetes treatment injection Ozempic in ...

Novo Nordisk launched Ozempic in India on Friday—and the weight-loss drug will sell at a massive discount there, compared ...